• Je něco špatně v tomto záznamu ?

A gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis

DE. Peters, LD. Norris, L. Tenora, I. Šnajdr, AK. Ponti, X. Zhu, S. Sakamoto, V. Veeravalli, M. Pradhan, J. Alt, AG. Thomas, P. Majer, R. Rais, C. McDonald, BS. Slusher

. 2023 ; 15 (708) : eabn7491. [pub] 20230809

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016594

Grantová podpora
K01 AT010984 NCCIH NIH HHS - United States
K01 OD030517 NIH HHS - United States
T32 OD011089 NIH HHS - United States
R25 GM143298 NIGMS NIH HHS - United States

There is an urgent need to develop therapeutics for inflammatory bowel disease (IBD) because up to 40% of patients with moderate-to-severe IBD are not adequately controlled with existing drugs. Glutamate carboxypeptidase II (GCPII) has emerged as a promising therapeutic target. This enzyme is minimally expressed in normal ileum and colon, but it is markedly up-regulated in biopsies from patients with IBD and preclinical colitis models. Here, we generated a class of GCPII inhibitors designed to be gut-restricted for oral administration, and we interrogated efficacy and mechanism using in vitro and in vivo models. The lead inhibitor, (S)-IBD3540, was potent (half maximal inhibitory concentration = 4 nanomolar), selective, gut-restricted (AUCcolon/plasma > 50 in mice with colitis), and efficacious in acute and chronic rodent colitis models. In dextran sulfate sodium-induced colitis, oral (S)-IBD3540 inhibited >75% of colon GCPII activity, dose-dependently improved gross and histologic disease, and markedly attenuated monocytic inflammation. In spontaneous colitis in interleukin-10 (IL-10) knockout mice, once-daily oral (S)-IBD3540 initiated after disease onset improved disease, normalized colon histology, and attenuated inflammation as evidenced by reduced fecal lipocalin 2 and colon pro-inflammatory cytokines/chemokines, including tumor necrosis factor-α and IL-17. Using primary human colon epithelial air-liquid interface monolayers to interrogate the mechanism, we further found that (S)-IBD3540 protected against submersion-induced oxidative stress injury by decreasing barrier permeability, normalizing tight junction protein expression, and reducing procaspase-3 activation. Together, this work demonstrated that local inhibition of dysregulated gastrointestinal GCPII using the gut-restricted, orally active, small-molecule (S)-IBD3540 is a promising approach for IBD treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016594
003      
CZ-PrNML
005      
20231026105708.0
007      
ta
008      
231013s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1126/scitranslmed.abn7491 $2 doi
035    __
$a (PubMed)37556558
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Peters, Diane E $u Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000341856203
245    12
$a A gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis / $c DE. Peters, LD. Norris, L. Tenora, I. Šnajdr, AK. Ponti, X. Zhu, S. Sakamoto, V. Veeravalli, M. Pradhan, J. Alt, AG. Thomas, P. Majer, R. Rais, C. McDonald, BS. Slusher
520    9_
$a There is an urgent need to develop therapeutics for inflammatory bowel disease (IBD) because up to 40% of patients with moderate-to-severe IBD are not adequately controlled with existing drugs. Glutamate carboxypeptidase II (GCPII) has emerged as a promising therapeutic target. This enzyme is minimally expressed in normal ileum and colon, but it is markedly up-regulated in biopsies from patients with IBD and preclinical colitis models. Here, we generated a class of GCPII inhibitors designed to be gut-restricted for oral administration, and we interrogated efficacy and mechanism using in vitro and in vivo models. The lead inhibitor, (S)-IBD3540, was potent (half maximal inhibitory concentration = 4 nanomolar), selective, gut-restricted (AUCcolon/plasma > 50 in mice with colitis), and efficacious in acute and chronic rodent colitis models. In dextran sulfate sodium-induced colitis, oral (S)-IBD3540 inhibited >75% of colon GCPII activity, dose-dependently improved gross and histologic disease, and markedly attenuated monocytic inflammation. In spontaneous colitis in interleukin-10 (IL-10) knockout mice, once-daily oral (S)-IBD3540 initiated after disease onset improved disease, normalized colon histology, and attenuated inflammation as evidenced by reduced fecal lipocalin 2 and colon pro-inflammatory cytokines/chemokines, including tumor necrosis factor-α and IL-17. Using primary human colon epithelial air-liquid interface monolayers to interrogate the mechanism, we further found that (S)-IBD3540 protected against submersion-induced oxidative stress injury by decreasing barrier permeability, normalizing tight junction protein expression, and reducing procaspase-3 activation. Together, this work demonstrated that local inhibition of dysregulated gastrointestinal GCPII using the gut-restricted, orally active, small-molecule (S)-IBD3540 is a promising approach for IBD treatment.
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    12
$a kolitida $x farmakoterapie $x metabolismus $7 D003092
650    _2
$a kolon $x patologie $7 D003106
650    _2
$a cytokiny $x metabolismus $7 D016207
650    _2
$a modely nemocí na zvířatech $7 D004195
650    12
$a glutamátkarboxypeptidasa II $x antagonisté a inhibitory $7 D043425
650    _2
$a zánět $x patologie $7 D007249
650    12
$a idiopatické střevní záněty $x farmakoterapie $x patologie $7 D015212
650    _2
$a myši inbrední C57BL $7 D008810
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Norris, Lauren D $u Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
700    1_
$a Tenora, Lukáš $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 160 00 Prague, Czechia $1 https://orcid.org/0000000269823545
700    1_
$a Šnajdr, Ivan $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 160 00 Prague, Czechia $1 https://orcid.org/0000000208314034
700    1_
$a Ponti, András K $u Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA $1 https://orcid.org/0000000186965038
700    1_
$a Zhu, Xiaolei $u Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/000000032733242X
700    1_
$a Sakamoto, Shinji $u Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/000000015498551X
700    1_
$a Veeravalli, Vijayabhaskar $u Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
700    1_
$a Pradhan, Manisha $u Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000287100148
700    1_
$a Alt, Jesse $u Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000154407891
700    1_
$a Thomas, Ajit G $u Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000159225050
700    1_
$a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 160 00 Prague, Czechia $1 https://orcid.org/0000000218046934
700    1_
$a Rais, Rana $u Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000340592453
700    1_
$a McDonald, Christine $u Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA $1 https://orcid.org/0000000267459487
700    1_
$a Slusher, Barbara S $u Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $u Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000198144157
773    0_
$w MED00177505 $t Science translational medicine $x 1946-6242 $g Roč. 15, č. 708 (2023), s. eabn7491
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37556558 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105702 $b ABA008
999    __
$a ok $b bmc $g 2000236 $s 1202956
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 15 $c 708 $d eabn7491 $e 20230809 $i 1946-6242 $m Science translational medicine $n Sci Transl Med $x MED00177505
GRA    __
$a K01 AT010984 $p NCCIH NIH HHS $2 United States
GRA    __
$a K01 OD030517 $p NIH HHS $2 United States
GRA    __
$a T32 OD011089 $p NIH HHS $2 United States
GRA    __
$a R25 GM143298 $p NIGMS NIH HHS $2 United States
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace